Rethinking Tradi.onal QA/QC: Weaknesses of Current Prac.ces; Six Sigma Metrics and Tools for Improvement

Similar documents
Rethinking Traditional Lab QA/QC:

Selecting a Risk-Based SQC Procedure for a HbA1c Total QC Plan

METHOD VALIDATION: WHY, HOW AND WHEN?

Patricia C. Fallest-Strobl, 1 Elin Olafsdottir, 2 Donald A. Wiebe, 1 and James O. Westgard 1 * Lipoproteins

A validation study of after reconstitution stability of diabetes: level 1 and diabetes level 2 controls

Agenda. 15 Dec

Individual Lab Report Ci-Trol Nov,2016. Abnormal Fibrinogen (mg/dl) Abnormal Fbg Control - Lot# LFC Your Lab

Method Comparison Report Semi-Annual 1/5/2018

It s Just a Waived Glucose, Isn t It?

Should HbA1C measured by POC instruments be used for diagnosis of diabetes? Sverre Sandberg, Norwegian Quality Improvement of Primary Care

The analytical phase

Analytical performance specifications two years after Milan conference. Prof Mauro Panteghini CIRME Scientific Coordinator

Dubrovnik 2014 Sverre Sandberg, Norwegian Quality Improvement of Primary Care Laboratories Noklus, Bergen, Norway

Uncertainty vs. total error in judging performance of participants Milano th International Meeting, CIRME

Setting of quality standards

Forum for Collaborative HIV Research External Validation of CD4 and Viral Load Assays Paris, France June 29, 2007

State of the Art of HbA1c Measurement

Understanding Quality Control for Infectious Disease Testing. Wayne Dimech ASLM Quality Control Workshop Abuja, Nigeria 9 th December 2018

Disclosures. Relevant Financial Relationship(s): Nothing to Disclose. Off Label Usage: Nothing to Disclose 9/19/2017. Proficiency Testing

Quality Control for Point-of-Care Testing

Placement of Biomarker Analysis in a CLIA or Bioanalytical Laboratory

4/10/2017. Placement of Biomarker Analysis in a CLIA or Bioanalytical Laboratory

Basic knowledge of POCT instuments. The Tide Resort Bangsan Beach 18 June 2009

Two Important Statistics

Special issue: Six Sigma metrics Original papers

Selecting a Hemoglobin A1C Point of Care Instrument. Objectives. Disclosure / Conflict of Interest 3/11/2015

GUIDE TO THE EVALUATION OF COMMUTABILITY OF CONTROL MATERIALS

Commutability studies undertaken by the LNE : the case of lipid and lipoprotein testing. Vincent Delatour, PhD

Traceability in External Quality Assessment: How Weqas ensures traceability in EQA and stresses its importance to users. David Ducroq.

LOGO. Department of Clinical Pathology, Faculty of Medicine Siriraj Hospital, Mahidol University & Thai Society of Clinical Pathology

Hemostasis Test Validation, Performance and Reference Intervals

INTERNAL QUALITY CONTROL ( Q I C) QC)

(a) y = 1.0x + 0.0; r = ; N = 60 (b) y = 1.0x + 0.0; r = ; N = Lot 1, Li-heparin whole blood, HbA1c (%)

Polymer Technology Systems, Inc. CardioChek PA Comparison Study

2014 Continuing Compliance Master Series Best Practices in Alternative Assessment of Performance

The challenges of quality assessment for point-of-care testing. Anne Stavelin. EQALM Symposium, Bergen 8 October General challenges

METHOD VALIDATION CASE

The study has been approved by Ethics Commission. Informed consent has been given by all participants.

Internal Quality Control in the Haemostasis laboratory. Dr Steve Kitchen Sheffield Haemophilia and Thrombosis centre & UK NEQAS Blood Coagulation

The Virtues and Pitfalls of Implementing a New Test

Problem with Traditional QC

Hurdles and Benefits of Implementing a QA Program Based on Patient Moving Averages

College of American Pathologists

External quality assessment schemes in Latin America

CONSULTORIAS INTEGRALS EN CALIDAD S.A.S. STEN WESTGARD, WESTGARD QC

Workshop on Proficiency Testing for Medical Laboratories. Daniel W. Tholen, M.S. March 13, 2013

What information on measurement uncertainty should be communicated to clinicians, and how? Mario Plebani

Deviations Inspection Observations & Issues to Consider for Achieving Compliance

College of American Pathologists (CAP) GH2 Survey Data: (updated 12/09) 2009 GH2-B (fresh pooled samples) * = NGSP certified at the time of the survey

Using Blood Glucose Meters in the Hospital: Defining Critically Ill and Addressing Accreditation Issues

Performance Characteristics of a New Single-Sample Freezing Point Depression Osmometer

METHOD VALIDATION CASE

Relationship between glucose meter error and glycemic control efficacy

Accuracy and Precision in Point-of-Care Lipid Testing: CardioChek P A Point-of-Care Test System and PTS Panels Test Strips

25-Hydroxy Vitamin D TOTAL (25HD) on Liaison XL

What I will talk about

QUANTIFYING THE EFFECT OF SETTING QUALITY CONTROL STANDARD DEVIATIONS GREATER THAN ACTUAL STANDARD DEVIATIONS ON WESTGARD RULES

Biological Variation The logical source for analytical goals

LEAF Marque Assurance Programme

Il ruolo delle VEQ per la sicurezza trasfusionale

Analytical Performance in the The Test Evaluation Cycle

Benefits and disadvantages of POCT

Topic: Q&A from CAP Webinar: Stay in Compliance With the CMS Directive Regarding PT Testing on Multiple Instruments Date: November 12, 2015

Internal Quality Control in the Haemostasis laboratory. Dr Steve Kitchen Sheffield Haemophilia and Thrombosis centre & UK NEQAS Blood Coagulation

BIOLOGICAL VARIABILITY: THE CIRME CONTRIBUTION. F. Braga Centre for Metrological Traceability in Laboratory Medicine (CIRME)

Cardiac Assessment Controls A critical element of reliable cardiac testing

Status of internal quality control for thyroid hormones immunoassays from 2011 to 2016 in China

Control of Foot-and-Mouth Disease

CLINITEK Novus Automated Urine Chemistry Analyzer

NICO /14 Nipro Diagnostics, Inc.

3 Linearity and Detection Limit Linearity Detection limit... 4

The effect of measurement uncertainty for HOMA-IR in assessment of insulin resistance

EVALUATION OF THE PERFORMANCE OF THE TRUETRACK BLOOD GLUCOSE MONITORING SYSTEM USING THE ISO 15197:2003 ACCURACY AND USER EVALUATION REQUIREMENTS

Patient Education. intermountainhealthcare.org/diabetes. BG Tracker. for people with diabetes MONITORING BLOOD GLUCOSE

Diabetes Monitoring: Easy as A-1-C An educational webinar sponsored by Siemens Healthcare Diagnostics

Individual Quality Control Plans (IQCP) Risk Assessment

CHALLENGES IN SIX SIGMA IMPLEMENTATION JAKARTA, DECEMBER 7TH, 2017

Point of Care Testing for INR using CoaguChek XS Plus

Farouk AL Quadan lecture 3 Implentation of

It s a Gas! Issues in the Blood Gas Laboratory. D. Robert Dufour, MD, FCAP Consultant Pathologist VA Medical Center, Washington DC

1. PROTOCOL. Comparison Study Summary. Tuality Healthcare 324 SE 9 th Ave. Suite E Hillsboro, OR July 30, 2014

Cardiac Assessment Controls

August 2017 Changes. Reproductive Laboratory Checklist. CAP Accreditation Program

liquicolor Design Verification

Quality Specifications for POCT

Practical relevance of measurement uncertainty in inborn errors of metabolism. Prof Jim Bonham Clinical Director Sheffield Children s NHS FT

Cap Laboratory Accreditation Manual Appendix B

Determination of hemoglobin is one of the most commonly

LAS-Q008. Proficiency Testing Requirements for Testing and Calibration Laboratories

The Whats and Hows of Reference Intervals. Graham Jones Department of Chemical Pathology St Vincent s Hospital, Sydney

UK NEQAS Low Level Leucocyte Enumeration Programme. Mr Matthew Fletcher Advanced Biomedical Scientist UK NEQAS for Leucocyte Immunophenotyping

The EUA Process at CDC Michael W. Shaw, PhD

EQA in POCT The Norwegian experience. Nina Gade Christensen Head of EQA, Noklus, Norway

Why Traceability Matters to Patients?

1 PROTOCOL. Comparison Study Summary

liquicolor (AMP Buffer, IFCC) Design Verification

Patient Safety: A Quality System Approach To POCT QC/QA

Advisory Committee Minutes

Defini&on of EQAS allowable limits for HBA1C: a candidate method

Transcription:

Rethinking Tradi.onal QA/QC: Weaknesses of Current Prac.ces; Six Sigma Metrics and Tools for Improvement James O. Westgard Sten A. Westgard Westgard QC, Inc. Madison, WI www.westgard.com 1

Hospitals recognize need for uniform lab test data Dark Report, Sept 9, 2013 ACOs have need for populakng the electronic health record with lab test data that has standardized reporkng forms and standardized reference ranges to allow physicians to track and trend pakent data in a meaningful way. Electronic Health Record needs to contain test results from POC, clinic, hospital, reference labs BUT, what if different methods in different labs don t provide standard consistent test results? 2

CAP 2013 HbA1c 7.11 %Hb 26 Method subgroups 7.9 6.1 3

Lack of conknuity problem ACO administrators recognize that having mulkple laboratories provide test data for the same pakent creates alack- of- conknuity problem. It means that physicians must sort through different lab test methodologies, different names for the same test, and different reference ranges. 4

But that s NOT the problem with HbA1c! All methods in use in US are cerkfied by the NaKonal Hemoglobin StandardizaKon Program (NGSP) to provide equivalent results Units are the same, %Hb Have standard diagnoskc & treatment targets Cut- off for diagnosis for diabetes is 6.5 %Hb Normals 5.6%Hb; 5.7 to 6.4 %Hb pre- diabekc Treatment goal is 7.0 %Hb 5

A rose is a rose is a rose! Why isn t a GHb a HbA1c or an NGSP A1c? 6

Errors in the Total TesKng Process Which errors have the most impact on inappropriate pakent care? Pre- analykc AnalyKc Post- analykc 7

What errors have been observed in the Total TesKng Process? Pre-analytic Analytic Post-analytic Ross & Boone. CDC, 1989 Conference Abstract 46% 7% 47% Plebani & Carraro. Clin Chem 1997:43:1348-51 68% 13% 19% Carraro & Plebani. Clin Chem 2007:53:1338-42 62% 15% 23% 8

Lab Errors and PaKent Care Plebani- Carraro Clin Chem 2007:53:1338-42 51,746 tests 393 queskonable results 160 confirmed as laboratory errors 46 caused inappropriate pakent care 24 of those were analykcal errors AnalyKcal errors are skll major cause (over 50% cases) of inappropriate pakent care 9

Plebani Clin Chem Lab Med 2007;45:700-7 detected analy,c errors are only the,p of the iceberg. Both laboratory professionals and clinicians currently acknowledge a restricted number of analy,cal errors for various reasons, ranging from the limited design of quality control procedures to poor response of clinicians to possible laboratory errors 10

Plebani Clin Chem Lab Med 2013;51:39-46 A beaer analy,cal quality should be achieved by sebng and implemen,ng evidence- based analy,cal quality specifica,ons; if this is done, rules for internal quality control and external quality assessment procedures would be more appropriate Finally, more stringent metrics, such as Six Sigma, should be largely introduced 11

Weaknesses in AnalyKcal Quality Management (AQA) - Plebani Current QC prac.ces are not adequate to detect medically important errors US has reduced QC requirements Proficiency teskng programs show poor performance when examined on the sigma scale External quality assessment schemes show laboratories do not comply with exiskng quality specificakons 12

Current QC PracKces What might be wrong? Quality Compliance, not control Minimum requirements now interpreted as maximums for purposes of cost control Influence of Equivalent Quality Control Protocols not scienkfically valid, but used anyway to qualify methods for reduced QC CMS s reliance on inspectors to be able to see problems though limle QC data to inspect 13

Weaknesses in AQM - Plebani Current QC prackces are not adequate to detect medically important errors US has reduced QC requirements Proficiency tes.ng programs show poor performance when examined on the sigma scale External quality assessment schemes show laboratories do not comply with exiskng quality specificakons 14

What does Six Sigma mean? - Tolerance Specification Target + Tolerance Specification -6 SDs should fit into spec +6 SDs should fit into spec -6s -5s -4s -3s -2s -1s 0s 1s 2s 3s 4s 5s 6s 15

How define tolerance specificakon? Proficiency TesKng (PT) or External Quality Assessment (EQA) criteria for acceptable performance Format of allowable Total Error, TEa US CLIA requirements Glucose Target Value ± 10% CAP requirements HbA1c Target Value ± 7.0% 16

How do you calculate sigma? Lower Tolerance Limit -TEa Sigma = TEa-Bias SD True Value Bias SD Upper Tolerance Limit +TEa -6s -5s -4s -3s -2s -1s 0s 1s 2s 3s 4s 5s 6s 17

Example calculakons HbA1c CAP TEa=7.0% Sigma = (%TEa - %Bias)/%CV TEa=7.0%, Bias=2%, CV=1% Sigma metric is (7-2)/1 or 5 sigma TEa=7.0%, Bias=1%, CV=1.5 Sigma metric is (7-1)/1.5 or 4 sigma TEa = 7.0%, Bias = 2%, CV=2% Sigma metric is (7-2)/2 or 2.5 sigma 18

Graphic Display of Sigma Quality (%bias=y- coord, %CV=x- coord) 7.0 Method Decision Chart HbA1c 7% Observed Inaccuracy, %Bias 6.0 5.0 4.0 3.0 2.0 1.0 6σ 2σ 0.0 0.0 1.0 2.0 3.0 Observed Imprecision, %CV 19

Proficiency TesKng Quality on the Sigma Scale (1) Review of quality of cholesterol, calcium, glucose, HbA1c, PSA, PPT, INR, fibrinogen Surveys by AAFP, MLE, AAB, API, CAP Number of CAP labs predominate Reference: Westgard JO, Westgard SA. The Quality of Laboratory TesKng Today: An assessment of sigma metrics for analykcal quality using performance from PT surveys and the CLIA criteria for acceptable performance. Am J Clin Pathol 2006;125:343-354. 20

PT Quality on the Sigma Scale (2) Cholesterol, TEa=10% Sigma 2.88 to 3.67 at 211 mg/dl, 9,258 labs Calcium, TEa=1.0 mg/dl Sigma 2.84 to 3.86 at 10.7 mg/dl, 9,786 labs Glucose, TEa=10% Sigma 2.95 to 4.00 at 121 mg/dl, 10,722 labs Remember baggage handling benchmark is about 4.0 sigma! 21

PT Quality on the Sigma Scale (3) Prothrombin Time, TEa=15% Sigma 1.77 to 5.35 at 16.8 sec, 800-900 CAP labs INR, TEa=20% Sigma 2.39 to 3.52 at 1.57, 800-900 CAP labs Fibrinogen, TEa=20% Sigma 1.78 to 3.24 at 260 mg/dl, 800-900 labs HbA1c, TEa=10% Sigma 1.93 to 2.57 at 9.0 %Hb, 5,066 labs 22

PT Quality on Sigma Scale (4) Prostate Specific AnKgen (PSA) NO CLIA defined criterion for acceptable performance PT data from 2,353 CAP labs SensiKvity analysis at 4.5 ng/ml 10% TEa (±0.45 ng/ml), Sigma 1.17 to 1.76 20% TEa (±0.9 ng/ml), Sigma 2.34 to 3.52 30% TEa (±1.35 ng/ml), Sigma 3.51 to 5.28 40% TEa (±1.8 ng/ml), Sigma 4.67 to 7.04 23

PSA Today! August 22, 2013: Thousands got faulty prostate cancer tests hmp://abcnews.go.com/health/thousands- faulty- prostate- cancer- tests/story?id=19985602&singlepage=true 7,500 pakents sent lemers because PSA results may have been falsely elevated during Feb 2012 to May 2013 due to reagent problem 20 to 23% posikve bias reported by manufacturer How many unnecessary biopsies? Treatment costs and consequences? 24

HbA1c 7.11%Hb Sigma Proficiency 2865 Labs, 26 Subgroups 7.00 CAP 2013 GH2-01 7.11%Hb Observed Inaccuracy (%Bias) 6.00 5.00 4.00 3.00 2.00 1.00 0.00 0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 4.5 5.0 5.5 6.0 Observed Imprecision (%CV) 25

Weaknesses in AQM - Plebani Current QC prackces are not adequate to detect medically important errors US has reduced QC requirements Proficiency teskng programs show poor performance when examined on the sigma scale External quality assessment schemes show laboratories do not comply with exis.ng quality specifica.ons 26

External Quality Assessment and Quality SpecificaKons Can current analykcal quality performance support evidence- based guidelines for diabetes and ischaemic heart disease? Jassam N, Yundt- Pacheco J, Jansen R, Thomas A, Barth JH. Clin Chem Lab Med 2013 (accessed online) Sigma performance for the median CV% for the par,cipant laboratories.. Was 3.3σ for HbA1c, 3.9σ for glucose, 2σ for crea,nine, 5σ for cholesterol, and 3.8σ for HDL- cholesterol. 27

EQA and Quality SpecificaKons Ref: Jassam et al The implementa,on of na,onal and interna,onal guidelines is beginning to standardise clinical prac,ce A scien,fically based quality control process will be a pre- requisite to provide the level of analy,cal performance which will support evidence- based guidelines and movement of pa,ents across boundaries while maintaining standardized outcomes. 28

A ScienKfically Based Six Sigma Quality System Must be driven by quality required for intended clinical use of laboratory tests Must validate method performance saksfies intended clinical use Must design QC to verify the aaainment of intended quality of test results Must monitor performance over Kme on the sigma- scale 29

Six System Quality System (1a) Regulatory & Accreditation Requirements (2a) Traceability (1) Define Goals for Plan Intended Use (TEa, Dint) (2) Select Analytic Measurement Procedure (1b) Clinical and Medical Applications (2b) Manufacturer s Reference Methods & Materials (4b) Pre-analytic and Post-analytic Requirements (12) Improve Analytic QC Plan [CQI, CAPA] (3) Validate Method Performance Do (CV,bias) (4) Implement Method and Analytic System (5) Formulate Sigma TQC Strategy (6) Select/Design SQC (rules, N) (3a) Manufacturer s Claims (4a) Manufacturer s Installation/Training Services (5a) Sigma [(TEa-Bias)/CV] (6a) Sigma QC Selection Tool Act (11) Monitor AQCP Failures [FRACAS] (Quality Indicators) Check (7) Develop (7a) Risk Analysis Analytic QC Plan (10) Measure Quality & Performance (EQA, PT) (8) Implement Analytic QC Plan (9) Verify Attainment of Intended Quality of Test Results (8a) QC Tools 30

Sigma Tools Six Sigma Quality System (1a) Regulatory & Accreditation Requirements (2a) Traceability (4b) Pre-analytic and Post-analytic Requirements (12) Improve QC Plan [CQI, CAPA] (11) Monitor Failures FRACAS, Quality Indicators (10) Measure Quality & Performance (EQA, PT) (1) Define Goals for Intended Use (TEa, Dint) (2) Select Analytic Measurement Procedure (3) Validate Method Performance (CV,bias) (4) Implement Method and Analytic System (5) Formulate Sigma TQC Strategy (6) Select/Design SQC (rules, N) (7) Develop Analytic QC Plan (8) Implement Analytic QC Plan (1b) Clinical and Medical Applications (2b) Method Manufacturer s Decision Reference Methods & Materials Chart, or (3a) Calculate Manufacturer s sigma [(TEa-bias)/CV] Claims (4a) Manufacturer s Installation/Training Services (5a) Sigma [(TEa-Bias)/CV] (6a) Sigma Sigma SQC Selection QC Selection Graph Tool or OPSpecs Chart (7a) Risk Analysis (8a) QC Tools Sigma Proficiency Assessment Chart (9) Verify Attainment of Intended Quality of Test Results 31

(1) Sigma Method ValidaKon Tool HbA1c (Bias=1.0%, CV=1.5%) 7.0 Method Decision Chart HbA1c 7% Observed Inaccuracy, %Bias 6.0 5.0 4.0 3.0 2.0 1.0 6σ 2σ 0.0 0.0 1.0 2.0 3.0 Observed Imprecision, %CV 32

(2) Sigma QC SelecKon/Design Tool Chart of OperaKng SpecificaKons 7.0 OPSpecs Chart TEa=7.0% w/0.90ped Observed Inaccuracy, %Bias 6.0 5.0 4.0 3.0 2.0 1.0 3.00 sigma performance 0.0 0.0 1.0 2.0 3.0 Observed Imprecision, %CV P fr N R 1 3s /2of3 2s /R 4s /3 1s /6 x 0.07 6 1 1 3s /2 2s /R 4s /4 1s 0.03 4 1 1 2.5s 0.04 4 1 1 3s 0.01 4 1 1 2.5s 0.03 2 1 1 /2 /R 3s 2s 4s 0.01 2 1 1 3s 0.00 2 1 33

(3) Sigma Proficiency Assessment Tool HbA1c, 2865 Labs, 26 Subgroups 7.00 CAP 2013 GH2-01 7.11%Hb Observed Inaccuracy (%Bias) 6.00 5.00 4.00 3.00 2.00 1.00 0.00 0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 4.5 5.0 5.5 6.0 Observed Imprecision (%CV) 34

Sigma quality vs necessary SQC 6 sigma process - single rule QC with 3.0s limits and N of 2 5 sigma process - single rule QC with 2.5s limits or mulkrule QC with Ns of 2-3 4- sigma process single rule QC with 2.5s limits or mulkrule QC with Ns of 4-6 3- sigma process need Ns of 6-8 or even higher, not prackcal for most laboratories Can t afford to run enough controls to detect medically important errors! 35

Future QC PracKces What might go wrong? New age of Risk- based QC Plans CLSI EP23A methodology qualitakve, subjeckve CMS appears to further simplify methodology Laboratories will not need to uklize tools such as process maps, fishbone diagrams, formal risk assessment charts and protocols in their development of an IQCP Laboratories face a steep learning curve to understand and correctly apply Risk QCPs 36

The Right Guidance! 37

ISO or CLSI or CLIA or YOU? 38

Thank you for your kind amenkon! 39